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higher medical costs in six European settings. METHODS: The Archimedes model
was used to simulate cohorts of individuals ages 40 to 75 with no prior history of
diabetes, cardiovascular disease, or chronic kidney disease, in Denmark, France,
Germany, Italy, Poland and the UK. Individuals were simulated for 10 years and the
incidences of diabetes and MACE were tracked, along with mean total medical
costs per person. A risk score was computed for each simulated person, with base-
line data on age, gender, BMI, waist, smoking, family histories of diabetes and
cardiovascular disease, and antihypertensive usage. For each country, the sub-
populations of individuals with above median risk score (TOP50), and individuals in
the top risk score quartile (TOP25) were compared to the full cohorts. RESULTS:
Diabetes and MACE incidences were higher in the TOP50 and TOP25 subgroups, as
were total medical costs. In each country, the mean 10-year discounted medical
costs for the full cohorts vs. the TOP50 subgroups were: Denmark €8,482 (95%CI
8,027 - 8,937) vs. €11,292 (10,614 - 11,969); France €6,264 (5,917 - 6,611) vs. €8,492
(7,953 - 9,031); Germany €8,717 (8,218 - 9,217) vs. €11,974 (11,204 - 12,743); Italy €7,688
(7,273 - 8,104) vs. €10,279 (9,643 - 10,914); Poland €1,798 (1,707 - 1,888) vs. €2,418
(2,274 - 2,561); UK €4,100 (3,885 - 4,314) vs. €5,580 (5,238 - 5,921). Medical costs were
even higher in the TOP25 subgroup. CONCLUSIONS: This risk score could be an
effective tool for identifying individuals likely to incur higher health care costs due
to diabetes and MACE. Targeting individuals with such scores could make screen-
ing programs more efficient, provided validation in real-world populations.
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BETA BLOCKERS FOR TREATMENT OF CHRONIC HEART FAILURE IN SPAIN:
REVIEW OF THE ECONOMIC EVIDENCE AND EFFICIENCY ANALYSIS
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OBJECTIVES: Chronic heart failure (CHF) is a major health issue because of its
growing prevalence, morbimortality and associated resource consumption. Beta
blockers have been shown to be effective and cost-effective therapies for CHF. The
aim is determining what beta blocker constitutes the most efficient therapy for CHF
patients in Spain. METHODS: Systematic review of primary (clinical trials) and
secondary (meta-analyses, clinical practice guidelines and economic assessments)
evidence on beta blockers for CHF issued before May 2012. Once that efficacy of
each beta blocker was established, local drug databases were accessed in order to
estimate the updated annual cost of each therapy and daily dose in Spain.
RESULTS: Given their similar efficacy [death RR: bisoprolol: 0.66, p0.0001; meto-
prolol: 0.66, p0.0001; carvedilol: 0.65, p0.005, nebivolol: 0.88, p0.21] and safety
profiles, international clinical guidelines on Cardiology recommend bisoprolol,
metoprolol succinate, carvedilol and nebivolol as first choice therapies for CHF
(class I and level of evidence A). Annual treatment costs per patient reached 38.70€;
162.53-311.69€; 170.70€ and 188.14€ for bisoprolol, carvedilol, metoprolol succinate
and nebivolol, respectively. When hospitalization costs are considered, cost per
avoided death was 9.512€, 14.989€, 16.767€ and 50.795€ for bisoprolol, carvedilol,
metoprolol succinate and nebivolol, respectively. Results of the cost-benefit anal-
ysis indicated that only bisoprolol showed a net benefit, with an estimated annual
savings of 116.293€. Budget impact analysis yields that bisoprolol implies a saving
of 76-88% of carvedilol cost of therapy per year and patient, 77% when compared to
metoprolol succinate and 79% versus nebivolol. CONCLUSIONS: Despite the unde-
ruse of betablockers for CHF treatment, they have demonstrated to be effective and
cost-effective. Among them, bisoprolol gathers pharmacologic, legal and phar-
macoeconomic characteristics that confirm their being the most efficient beta
blocker (both in terms of cost-benefit and cost-effectiveness) for CHF patients in
Spain.
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THROMBOSIS AND EMBOLISM PREVENTION IN ORTHOPEDIC PATIENTS IN
RUSSIA
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OBJECTIVES: New anti-thrombotic strategy with recent low-molecular-weight
heparins (LMWHs) used for the prevention of symptomatic deep venous thrombo-
sis and pulmonary embolism (DVT/PE) has shown clinical and outcome benefits in
patients undergoing orthopedic surgery. The purpose of our study is to analyze the
costs of LMWHs in total knee replacement and to compare cost-effectiveness and
budget impact of bemiparin and enoxaparin addition to current treatment of such
patients in Russia. METHODS: Cost-effectiveness analysis and budget impact
model of patients with total knee replacement (n1000) is used to compare alter-
native strategies with bemiparin and enoxaparin for deep venous thrombosis and
pulmonary embolism prevention. The model calculates the budget impact of in-
hospital LMWHs drug therapy change for these patients. Only direct costs of med-
icines were considered. The prices of medications were taken from the official price
listing. Rates of main outcome were based on literature data (confirmed venous
thromboembolism 32.1% for bemiparin and 36.9% for enoxaparin). Net budget im-
pact was expressed as a difference in costs between the strategies where bemiparin
is gradually elevated versus traditionally enoxaparin prevention. The budget im-
pact is reported in terms of additional annual total costs. RESULTS: According to
the model, prevention of DVT/PE with bemiparin in total knee replacement was
dominant when compared to enoxaparin. Scenario of the introduction of bemi-
parin reduces budget costs for LMWHs drugs (in case 50% bemiparin and 50%
enoxaparin for 130.9 RUB / patient). In case of 100% bemiparin it can provide actual
DVT/PE prevention in 117 additional patients with total knee replacement.
CONCLUSIONS: Bemiparin demonstrated optimal cost-effectiveness and budget
savings compared to enoxaparin in total knee replacement. Further steps such as
including bemiparin in clinical recommendations and medical standards of care
for the patients is needed for implementing bemiparin in routine hospital practice.
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OBJECTIVES: Evidence on the use of newer antiplatelet agents and their cost im-
plications remains scarce. Previous research has shown a shorter average hospital
length of stay for prasugrel-treated patients compared to clopidogrel-treated pa-
tients. We analyzed a large geographically diverse database from the US and com-
pared cost of hospitalization for patients with acute coronary syndrome (ACS) who
have undergone percutaneous coronary intervention (PCI) and who received either
clopidogrel or prasugrel. METHODS: Using a large representative US database
maintained by PREMIER, we analyzed patient characteristics and total hospitaliza-
tion costs during the index (first) hospitalization among ACS-PCI patients treated
with clopidogrel or prasugrel between July 2009 and June 2011. Analysis included
patients treated with prasugrel who were on-label and clopidogrel-treated patients
who would have been eligible for prasugrel treatment per the label. Observed costs
were analyzed unadjusted and adjusted for baseline differences using a general-
ized linear model with a gamma distribution and log link function with propensity
score stratification. RESULTS:Data were available for 75,315 patients who received
clopidogrel and 9,483 patients who received prasugrel during their hospitalization.
The observed mean hospitalization costs (SD) for clopidogrel and prasugrel, respec-
tively, were $17,519 ($2,548) and $17,136 ($2,562). Mean costs for clopidogrel and
prasugrel recipients, respectively, were $16,937 ($2,162) and $16,664 ($2,137) for
STEMI, $17,926 ($2,747) and $17,511 ($2,849) for NSTEMI, and $17,900 ($2,665) and
$17,393 ($2,676) for UA (all comparisons, P0.001). The adjusted results showed
prasugrel-treated patients cost as much as $882 less than clopidogrel-treated pa-
tients (P0.001) during the index hospital stay. CONCLUSIONS: Prasugrel-treated
patients used fewer health care resources compared to clopidogrel-treated pa-
tients during the index hospital stay, as measured by hospital costs. Similar results
were obtained after adjusting for patient demographics and clinical characteris-
tics. The potential for unmeasured confounder bias is a limitation in this real-world
observational research.
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OBJECTIVES:The PLATO trial showed that ticagrelor reduced the risk of myocardial
infarction, stroke or death from vascular causes compared to clopidogrel (hazard
ratio 0.84, 95% CI 0.77 to 0.92) without a significant increase in major bleeding. The
objective of this analysis is to evaluate direct and indirect costs of ticagrelor versus
branded clopidogrel in patients with acute coronary syndromes (ACS) from a Rus-
sian health care perspective. METHODS: An excel based model was developed to
estimate the direct and indirect cost per treatment arm for specific CV events (non
fatal MIs, CV deaths and other deaths). Rates of non fatal myocardial infarction
(MI), CV death and death from other causes was extracted from the PLATO trial
(NCT00391872). Difference in direct medical and non-medical costs for ticagrelor vs
clopidogrel in patients was estimated using the events above. One-way sensitivity
analysis was performed. RESULTS: The result of this analysis shows that ticagrelor
is associated with reduced health care costs compared with branded clopidogrel for
one year treatment in a Russian health care setting. The incremental drug costs of
ticagrelor (- 264.46 RUB (€6.48) per patient per year) was offset by higher non drug
costs associated with fewer MI’s and deaths. Treatment with ticagrelor for one year
is associated with total cost savings of 2749.97 RUB (€67.37) per patient, the direct
cost savings was of 1260.83 (€30.89) and the indirect was 1489.13 RUB (€36.48) Sen-
sitivity analysis showed that ticagrelor remains to be cost saving compared to
branded clopidogrel as long as the ticagrelor price is less than 3520.94 RUB (€86.25)
per package while keeping other model parameters unchanged. CONCLUSIONS:
This analysis demonstrates that one year treatment with ticagrelor is less costly
than branded clopidogrel for patients with ACS from a Russian health care perspec-
tive.
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PATIENTS WITH ACUTE ISCHEMIC STROKE IN UKRAINE
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OBJECTIVES: Two approaches recanalization or restoration of adequate perfusion
and neuroprotection are identified as a pathogenic treatment of acute ischemic
stroke (AIS). Timely mechanical revascularization and thrombolytic therapy pre-
vent the development of neurons necrosis and significantly improve survival and
quality of patient life. Unfortunately, in Ukraine these methods are difficult of
access for patients due to high cost, late diagnostics and contraindications. The
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feasibility of combined neuroprotection in patients with AIS convincingly are sub-
stantiated by leading Ukrainian neurologists. The aim is to evaluate the economic
feasibility of combined regimens of neuroprotection compared with the
traditional. METHODS: Analysis of the results of comparative clinical trial of three
neuroprotective regimens therapy of patients with moderate and severe AIS: tra-
ditional  citicoline (1 regimen); traditional  citicoline  actovegin (2 regimen); 3
regimen: traditional (pentoxifylline, heparin, acetylsalicylic acid, mannitol) (S. M.
Vinychuk, O. A. Pustova, V.O. Mokchnach et al., 2008) was carried out. Cost-effec-
tiveness analysis was used. Using a decision tree comparing the economic burden
of the three regimens for one year was carried out. RESULTS: The number of pa-
tients who recovered completely after three months were used as efficacy. The
efficacy for 1, 2 and 3 regimens were respectively 29.6%, 38.9% and 23.3%. Direct
costs of the treatment regimens were $ 1.015; $ 1.186; $ 617 for 1, 2 and 3 regimens,
respectively. Incremental cost-effectiveness ratio (ICER) for 1 and 2 regimens were
respectively $6.317, $3.647. The economic burden per one patient for one year were
$ 7006; $ 6511; and $ 6930 for 1, 2 and 3 regimens, respectively. CONCLUSIONS: The
use of regimen 1 and regimen 2 provides greater efficacy and needs greater cost.
With the forecast for one year and taking into account the indirect costs the neu-
roprotective regimen with combination of two drugs (regimen 2) has economic
advantages.
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OBJECTIVES: The prevalence of atrial fibrillation (AF) in France approaches one
million people. The major complication associated with AF is stroke. Current anti-
coagulation options for stroke prevention increase the risk of hemorrhages. Objec-
tives were to estimate the 2-year cumulative incidence and costs of hospitaliza-
tions for strokes and hemorrhages in adults hospitalized for AF and eligible for
stroke prevention. METHODS: Data for patients with an AF-related hospitalization
in 2008 were extracted from the French Hospital National Database (PMSI). Risk
scores (i.e.CHADS2; range:0–6) were calculated from 2006–2008 data. Patient eligi-
ble for stroke prevention with anti-coagulants (i.e.CHADS21) were selected for
the follow-up analysis. Strokes and hemorrhages hospitalizations were identified
according to ICD-10 codes. Strokes severity was based on rehabilitation length and
death. Cumulative incidence was calculated by the number of new hospitalizations
during the 2-year period divided by the number of patients. Mean hospital costs
were calculated from to the 2011 National Hospital Tariff for acute and rehabilita-
tion care. RESULTS: A total of 61,582 AF patients were identified. Mean age was
75.0(11.0) years old and mean CHADS2 was 1.90(0.99). 2-year cumulative inci-
dences of any strokes and hemorrhages were 3.21% (ischemic/60%; hemorrhagic/
24%; unspecified/16%) and 5.31% (gastro-intestinal/26%; intracranial/5%; others/
69%), respectively. Mean costs of ischemic and hemorrhagic strokes were €4,848
and €7,183 (mild), €10,909 and €14,298 (moderate), €29,065 and €29,701 (severe) and,
€6,035 and €4,590 (fatal), respectively. Mean costs of hemorrhages were €3,601 and
€7,331 for gastro-intestinal and intracranial localizations and, €3,941 and €2,552 for
others major and non-major hospitalized bleeds. CONCLUSIONS: Frequencies and
cost of hospitalized hemorrhages appear important to be taking into account in the
global burden of AF. This data should be useful for future French pharmacoeco-
nomic evaluations of new oral anti-coagulants. Thus, this real world data study
may be helpful to assess consistency of patients’ features within recent published
clinical trials.
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OBJECTIVES: To estimate the health care resource utilization and direct costs of
cardioembolic stroke in patients treated in public hospitals of the Region of Madrid
(Spain). METHODS: An observational, prospective study was performed in 5 Neu-
rology services from hospitals in the Region of Madrid, 2 with stroke units (SU) and
3 without stroke units (wSU). Patients with a diagnosis of cardioembolic stroke with
48-hours were recruited in a 4-month period in 2012. Patients’ socio-demo-
graphic, clinical data: disability (modified Rankin scale, mRs), hospital stay and
mortality; complications and health care resource utilization (hospitalisation, in-
patient and at discharge rehabilitation, medication, laboratory tests and specific
therapeutic interventions) were collected. Unitary costs were obtained from na-
tional health care database and the Spanish Catalogue of Medicinal Products (€,
year 2012). RESULTS: Preliminary results from 76 patients (25 SU, 51 wSU) were:
mean age, 74.21.42; 64.5% female; mean mRs at discharge, 2.020.20; non-valvu-
lar atrial fibrilation was the main cause of cardioembolic stroke (28.9%); mean
length of stay, 10.11.14 days; mortality, 5.3%; 42 patients (68.4%) needed in-pa-
tient rehabilitation and 48 patients (63.2%) needed rehabilitation after hospital
discharge; 22 patients (28.9%) suffered hospital complications (63.6% of them suf-
fered infections, 27.3% cardiovascular complications and 59.1% others). Health care
resource utilization differences between SU and wSU hospitals were found in:
length of stay (7.21.26 days, SU; 11.61.55 days, wSU; p-value0.014) and specific
therapeutic interventions (41.7%, SU; 8.0%, wSU; p-value0.001). The overall
4-month cost per patient was 13,647€ (49.2%, hospital stay; 24.8%, rehabilitation at
discharge). CONCLUSIONS: Cardioembolic stroke imposes significant economic
burden for the Public Health System in the Region of Madrid. Key cost drivers were
hospital stay and patients’ rehabilitation at discharge. Patient management in SU
hospitals was associated with more specific therapeutic interventions and shorter
hospital stay than hospitals wSU.
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OBJECTIVES: To evaluate the annual acute and long-term hospitalizations cost of
MR from a French National Payer perspective. METHODS: A 12 months retrospec-
tive population-based study was conducted using the 2009–2010 French Medical
Information System (PMSI). This exhaustive database covers all public and private
hospitals in France and it is based on standardized hospital discharge reports. Each
patient is identified using a unique anonymous identification number allowing a
longitudinal follow-up. Extracted variables included patients’ demographics, out-
comes, acute hospital and post-discharge resource utilizations. RESULTS: 19,868
MR patients were identified and analyzed in two sub-groups depending on their
therapeutic management. In the surgical group (n4,099), the index hospitaliza-
tion length of stay was 17 days, 77% of patients were discharged to a rehabilitation
facility and the average re-hospitalization rate was of 33% over a 6 month period.
The average total cost per patient was €22.152. In the non-surgical group
(n15,769), patients were hospitalized on average 3.1 times over 12 months with an
average length of stay of 7.7 days. Among those patients, 24% were admitted to a
rehabilitation facility (on average 1.5 times) with an average length of stay of 27.9
days. The average total cost per patient was €12.177, varying between €9.957 to
€13.538, without and with heart failure respectively. Detailed analysis showed 2 to
3 times higher costs in the 9th and 10th percentiles. By sub-group, the average cost
of the 10th percentile was €50.268 for the surgical group and €36.503 for the non-
surgical group. CONCLUSIONS: The total observed cost in this population was €283
million over 12 months. Significant differences were observed in cost and resource
used between the surgical and non-surgical groups and depending on type of sur-
gery or presence of heart failure within each subgroup. This is the first study re-
porting hospital costs associated to MR in France.
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OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’
of mortality, morbidity and economic losses. The aim of this study was to estimate
the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS:
For the purpose of the study CVD was defined by the International Classification of
Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis-
ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence,
top-down method was used to quantify the annual cardiovascular costs. Produc-
tivity losses were estimated using the human capital approach and the friction cost
method. Data were collected from Serbian Health Insurance Fund and National
Public Health Institute “Batut”. A discount rate of 5% was used to convert all future
lifetime earnings into the present value. RESULTS: The total direct costs of CVD in
2009 were € 400 million. The majority of total costs (€ 514.3 million) were for:
medication (29.94%), hospital days (28.97%) and hospital inpatient care – surgical
and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac-
counted for 22.15% of total costs. The results showed that more than half a million
working days were lost due to incapacity resulting from CVDs. The results were
robust to a change in20% of volume or the unit price of all direct and indirect cost
and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre-
sented approximately 1.8% of the Serbian gross domestic product. The results of
study would be valuable to health policy makers to bridge the gap between in-
vested resources and needs, in order to improve cardiovascular disease outcomes.
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IMS Health, Vilvoorde, Belgium
OBJECTIVES: The risk of cardiovascular risk is higher in patients with diabetes but
what with the cost of this complication? The aim of this study was to compare the
cost of cardiovascular events in patients with and without diabetes in Belgium.
METHODS: Cost of cardiovascular events among hospitalized patients were esti-
mated using the longitudinal IMS Hospital Disease Database (2008), including data
on 34.3% of Belgian hospital beds, combined with Belgian population data. Stays
were identified based on ICD-9 or DRG coding. Cardiac disease included myocardial
infarction (MI; ICD-9:410), angina (ICD-9: 413) and heart failure (ICD-9: 428). Cere-
brovascular disease (CVD) was defined as stroke (APR-DRG:045;046) and Transient
Ischemic Attack (TIA; DRG:047). Diabetes was defined with the ICD-9 codes 249 and
250. Cost comparisons were made using a Wilcoxon non-parametrical test.
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